COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature

Since the declaration of COVID-19 as a pandemic in 2020, several therapies have been developed to reduce symptoms of COVID-19 infection and prevent progression. Paxlovid is an antiviral that was authorized for emergency use in December 2021 for non-hospitalized symptomatic patients with COVID-19 to...

Descripción completa

Detalles Bibliográficos
Autores principales: Alshanqeeti, Shatha, Bhargava, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308388/
https://www.ncbi.nlm.nih.gov/pubmed/35898366
http://dx.doi.org/10.7759/cureus.26239
_version_ 1784752973347291136
author Alshanqeeti, Shatha
Bhargava, Ashish
author_facet Alshanqeeti, Shatha
Bhargava, Ashish
author_sort Alshanqeeti, Shatha
collection PubMed
description Since the declaration of COVID-19 as a pandemic in 2020, several therapies have been developed to reduce symptoms of COVID-19 infection and prevent progression. Paxlovid is an antiviral that was authorized for emergency use in December 2021 for non-hospitalized symptomatic patients with COVID-19 to prevent progression to severe disease. Relapse of symptoms following a period of improvement after treatment with Paxlovid has been described recently. Data are limited, but the disease course in available case reports is usually mild and requires no additional antiviral treatment. We present the cases of COVID-19 relapse (COVID-19 rebound) in two patients following treatment with Paxlovid.
format Online
Article
Text
id pubmed-9308388
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-93083882022-07-26 COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature Alshanqeeti, Shatha Bhargava, Ashish Cureus Infectious Disease Since the declaration of COVID-19 as a pandemic in 2020, several therapies have been developed to reduce symptoms of COVID-19 infection and prevent progression. Paxlovid is an antiviral that was authorized for emergency use in December 2021 for non-hospitalized symptomatic patients with COVID-19 to prevent progression to severe disease. Relapse of symptoms following a period of improvement after treatment with Paxlovid has been described recently. Data are limited, but the disease course in available case reports is usually mild and requires no additional antiviral treatment. We present the cases of COVID-19 relapse (COVID-19 rebound) in two patients following treatment with Paxlovid. Cureus 2022-06-23 /pmc/articles/PMC9308388/ /pubmed/35898366 http://dx.doi.org/10.7759/cureus.26239 Text en Copyright © 2022, Alshanqeeti et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Infectious Disease
Alshanqeeti, Shatha
Bhargava, Ashish
COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
title COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
title_full COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
title_fullStr COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
title_full_unstemmed COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
title_short COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature
title_sort covid-19 rebound after paxlovid treatment: a case series and review of literature
topic Infectious Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308388/
https://www.ncbi.nlm.nih.gov/pubmed/35898366
http://dx.doi.org/10.7759/cureus.26239
work_keys_str_mv AT alshanqeetishatha covid19reboundafterpaxlovidtreatmentacaseseriesandreviewofliterature
AT bhargavaashish covid19reboundafterpaxlovidtreatmentacaseseriesandreviewofliterature

Ejemplares similares